DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder

Information source: Nanjing Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depressive Disorder

Intervention: SSRI antidepressants (Drug); Cognitive-Behavior Therapy (Behavioral)

Phase: Phase 4

Status: Recruiting

Sponsored by: Nanjing Medical University

Official(s) and/or principal investigator(s):
Chun Wang, doctor, Principal Investigator, Affiliation: Nanjing Medical University

Overall contact:
Chun Wang, doctor, Phone: 86 15850566376, Email: fm51109@163.com

Summary

Study hypothesis: psychotherapy and SSRI treatment effect in different brain way: psychotherapy in "up to down" way and SSRI in "down to up" way. The investigators will explore this hypothesis in major depressive disorder outpatients with Magnetic Resonance Imaging analysis in this study. Patients in different groups will be treated by psychotherapy or SSRI treatment. They will all be checked with Magnetic Resonance Imaging pro and after 12 weeks of treatment.

Clinical Details

Official title: Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Hamilton Rating Scale for Depression (HAMD)

Secondary outcome: Magnetic Resonance Imaging

Detailed description: Patients meeting the inclusion criteria undergo an examination that included a diagnostic interview, vision test, and psychophysiological measures. Participants then undergo the baseline fMRI scan within 48 hours, after that, they will receive psychotherapy or SSRI treatment. and returned the scan once they completed the therapy.

Eligibility

Minimum age: 20 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- meet SCID -Ⅰ/P major depressive disorder diagnosis;

- Right handedness;

- good visual acuity.

Exclusion Criteria:

- neurological disease ;

- serious physical illness (e. g. heart, lung, liver, kidney or blood system disease);

- with other mental disorder;

- psychotic symptoms

- personality disorders;

- pregnancy;

- suicidal risk;

- treatment by antidepressants or other psychotropic medications within 6 months prior

to the start of the trial;

- with contraindication for MRI

Locations and Contacts

Chun Wang, doctor, Phone: 86 15850566376, Email: fm51109@163.com

Nanjing Brain Hospital, Nanjing, Jiangsu 210029, China; Recruiting
Chun Wang, Principal Investigator
Additional Information

Starting date: December 2011
Last updated: September 24, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017